OLD National Bancorp IN Sells 16,066 Shares of Edwards Lifesciences Corporation $EW

Key Points

• OLD National Bancorp IN sold 16,066 shares, cutting its Edwards Lifesciences stake by 27.5% in Q4 and leaving it with 42,355 shares valued at about $3.61 million.
• Significant insider and institutional selling — over the past 90 days insiders sold 86,058 shares (≈$7.12M), including VP Donald Bobo Jr.'s 22,680‑share sale (executed under a Rule 10b5‑1 plan), which could add near‑term selling pressure.
• Fundamentals: mixed but upbeat — Edwards beat Q1 estimates (EPS $0.78 vs. $0.73; revenue $1.65B, +16.7% YoY) on strong valve demand, yet guidance was only roughly in line and the stock trades at a high P/E (~43.6), leaving it vulnerable to profit‑taking.

OLD National Bancorp IN decreased its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 27.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,355 shares of the medical research company's stock after selling 16,066 shares during the quarter. OLD National Bancorp IN's holdings in Edwards Lifesciences were worth $3,611,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. Dorato Capital Management bought a new position in shares of Edwards Lifesciences during the 4th quarter worth $29,000. True Wealth Design LLC grew its position in shares of Edwards Lifesciences by 251.5% during the 3rd quarter. True Wealth Design LLC now owns 362 shares of the medical research company's stock worth $28,000 after buying an additional 259 shares in the last quarter. Rakuten Securities Inc. grew its position in shares of Edwards Lifesciences by 413.7% during the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company's stock worth $29,000 after buying an additional 302 shares in the last quarter. Finally, Hantz Financial Services Inc. grew its position in shares of Edwards Lifesciences by 76.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company's stock worth $29,000 after buying an additional 164 shares in the last quarter. Institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 22,680 shares of the firm's stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the sale, the vice president owned 21,266 shares of the company's stock, valued at approximately $1,704,682.56. This trade represents a 51.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Daniel J. Lippis sold 1,019 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $80.98, for a total value of $82,518.62. Following the completion of the sale, the vice president directly owned 33,934 shares of the company's stock, valued at approximately $2,747,975.32. This represents a 2.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 86,058 shares of company stock valued at $7,118,636. 0.31% of the stock is currently owned by corporate insiders.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Strong underlying demand and an overall beat — management said robust demand for its artificial/complex heart valves drove outperformance and Reuters noted the company topped quarterly estimates; that pushed shares higher in after-hours trading. Article Title
• Positive Sentiment: Revenue growth: reported revenue of about $1.65B (+16.7% YoY), roughly beating the revenue estimate — supports ongoing top-line momentum in core valve businesses. Article Title
• Neutral Sentiment: Guidance is roughly in line with consensus but not clearly bullish — Q2 EPS guided to $0.70–$0.76 (consensus ~ $0.75) and FY EPS to $2.95–$3.05 (consensus ~ $2.97); revenue range $6.5B–$6.9B vs a ~$6.7B consensus, leaving investors focused on the midpoint and execution risk.
• Neutral Sentiment: Company-reported EPS/metrics show improvement (MarketBeat/press release notes an EPS beat vs some estimates), but reporting differences across outlets create short-term interpretation noise. Article Title
• Negative Sentiment: Conflicting EPS figures and measure differences — one data source (Quiver) shows diluted EPS below estimates, which can spook investors who focus on GAAP vs. adjusted reconciliation and raise uncertainty about the quality of the beat. Article Title
• Negative Sentiment: Insider selling and large recent institutional rebalances noted in filings (documented by Quiver) can add selling pressure or reduce investor confidence in the near term. Article Title
• Negative Sentiment: High valuation (P/E in the mid‑40s) and a recent strong run mean the name is vulnerable to profit-taking when guidance or metrics are viewed as only modestly better — that likely contributes to today's weakness.

Edwards Lifesciences Stock Performance

EW stock opened at $79.69 on Friday. The firm has a market cap of $45.95 billion, a price-to-earnings ratio of 43.55, a PEG ratio of 2.12 and a beta of 0.95. The firm has a 50-day simple moving average of $81.54 and a two-hundred day simple moving average of $82.15. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $87.89. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.09 and a current ratio of 3.72.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The company's quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, equities analysts forecast that Edwards Lifesciences Corporation will post 2.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on EW. Truist Financial set a $89.00 price objective on Edwards Lifesciences and gave the company a "hold" rating in a research report on Wednesday, February 11th. UBS Group reissued a "neutral" rating and set a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. The Goldman Sachs Group reissued a "buy" rating and set a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price target on shares of Edwards Lifesciences and gave the company a "buy" rating in a research report on Tuesday, January 20th. Finally, Weiss Ratings reissued a "hold (c)" rating on shares of Edwards Lifesciences in a research report on Monday. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $95.74.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.